🎥Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, @HKUniversity, shares highlights from the #MetastaticBreastCancer track at #ESMO25 - including updates from VIKTORIA-1, novel ADCs in #TNBC, and PRO/QoL insights. Watch here ➡️ buff.ly/E4FLjXD #BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #ESMO25

Emmanuel Seront, MD, PhD, discusses the Phase II RENALUT trial of 177Lu-PSMA-617 in metastatic ccRCC post-TKI/IO therapy, exploring PSMA-targeted radioligand therapy as a new option for resistant disease 🎥 buff.ly/dLhijGf #KidneyCancer #KCSM #CTSM #TrialUpdate #RadioligandTherapy #RadOnc #ESMO25

Charles Geyer, MD, reports #DESTINYBreast05 results in HER2+ early BC. 💊 T-DXd > T-DM1 for iDFS & DFS 🧠 Reduced brain mets risk ⚖️ Manageable safety → potential new SoC 🎥 buff.ly/r3AwOkw #BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #Immunotherapy #HER2 #ESMO25 @myesmo.bsky.social

Nima Nabavizadeh, MD, presents #PATHFINDERII data on multi-cancer early detection. 🧬 cfDNA test detects cancer signal & origin 📈 High specificity & PPV ⚕️ Boosted early-stage cancer detection 🎥 buff.ly/LDR0AgW #CancerScreening #Oncology #ESMO25

Neal Shore, MD, FACS shares final OS data from EMBARK in high-risk BCR prostate cancer. 💊 Enzalutamide + leuprolide ↓ risk of death vs leuprolide alone 📈 Improved progression & skeletal outcomes ✅ Confirms enzalutamide-based therapy as SoC 🎥 buff.ly/LBEmrOa #ProstateCancer #ESMO25 #UroOnc #UroSoMe

Alexandra Drakaki, MD, PhD, discusses FORAGER-1 testing LY3866288 in FGFR3-altered tumors 🧬 200 mg BID = well tolerated 💥 Encouraging antitumor activity in mUC 🧪 Activity seen post-FGFR inhibitor exposure 🎥 buff.ly/ozWqgdG #BladderCancer #Blcsm #UroOnc #UroSoMe #CTSM #TrialUpdate #ESMO25

Shigehira Saji, MD, PhD, shares final OS data from EMERALD in 1L HER2+ #BreastCancer. 💊 Eribulin or taxane + trastuzumab + pertuzumab 📈 Median OS >6 years, similar across arms 🧬 PIK3CA = poor prognosis, no impact on treatment effect 🎥 buff.ly/R9sZAVk #BCSM #TrialUpdate #CTSM #ImmunoOnc #ESMO25

Andreas Dietz, MD, PhD, discusses the ADRISK Phase IIb trial in adjuvant HNSCC. 💉 Pembrolizumab + chemoradiation ➡️ No sig. EFS/OS gain, but favorable trends ⚖️ Safety consistent; supports further study 🎥 buff.ly/NlJqVv0 #HNSCC #Immunotherapy #Oncology #ESMO25

At #ESMO25, Enrique Grande, MD, presents results from the Phase II DISCUS trial in aUC. 💊 3 vs 6 chemo cycles before avelumab maintenance 📈 Similar OS & PFS 💪 Better QoL & fewer toxicities with 3 cycles 🎥 buff.ly/UjqkfNT @myesmo.bsky.social #BladderCancer #ImmunoOnc #GUcancer #Oncology

Clara Steiner, MD, presents new transcriptomic findings from COSMIC-313 in #RCC at #ESMO25 🧬 RNA sequencing of baseline tumors 🔍 Distinct gene signatures by metastasis site 🌡️ Pathways: metabolism, hypoxia, EMT 🎥 Watch: buff.ly/dIMvnoC @myesmo.bsky.social #KCSM #CTSM #TrialUpdate #UroOnc #UroSoMe

Alexander Wyatt, DPhil, shares IMvigor011 results of ctDNA-guided adjuvant atezolizumab in high-risk #BladderCancer: 🧬 Atezolizumab improved DFS & OS in ctDNA+ pts 🚫 ctDNA– pts had low recurrence risk ✅ Safety consistent with known profile 🎥 Watch: buff.ly/g35zqx2 @myesmo.bsky.social #ESMO25

At #ESMO25, Shigehira Saji shares new MonarchE data on Ki-67 as a biomarker in HR+/HER2– high-risk #BreastCancer: 📊 High Ki-67 = ↑ recurrence risk 💊 Abemaciclib + ET effective across all Ki-67 subgroups ✅ Broad benefit, regardless of Ki-67 change 🎥 Watch: buff.ly/F1mziDY #BCSM #CTSM #TrialUpdate

At #ESMO25, Scott Tagawa, MD, MS, FACP, discusses the Phase III PSMAddition trial in PSMA-positive mHSPC: 💥 Adding ¹⁷⁷Lu-PSMA-617 to ADT + ARPI improved rPFS 📈 OS trend & manageable safety ✅ No major QoL impact 🎥 Watch: buff.ly/vSBfVPS @myesmo.bsky.social #PCSM #UroOnc #UroSoMe #RadOnc #CTSM

At #ESMO25, Clara Steiner, MD, presents 5-year results of CheckMate 274 in MIUC 💊 Adjuvant nivolumab vs placebo after surgery 📈 Sustained DFS, OS & disease-specific survival benefit 🧫 ctDNA-positive pts saw enhanced benefit ✅ No new safety concerns 🎥 Watch: buff.ly/ou4EvLv #UroOnc #UroSoMe #Blcsm

At #ESMO25, Stephanie Graff, MD, addresses key questions in #BreastCancer care. 💊 Updates on CDK4/6 inhibitors 💪 Managing endocrine therapy toxicities 🌍 Global survivorship & trial access insights 🎥 Watch the full session: buff.ly/LdOXB18 #BCSM #Oncology

At #ESMO25, Emmanuel Seront discusses the RENALUT trial of ¹⁷⁷Lu-PSMA-617 in metastatic ccRCC 💥 PSMA-targeted radioligand therapy after TKI + ICI progression 🎯 Evaluating response, PFS, OS, & safety 🧠 Imaging-guided treatment w/ added cycles for responders 🎥 buff.ly/sswLUyk #kcms #UroOnc #UroSoME

🎥Prof. Jun Ma of Sun Yat-sen University Cancer Center, Guangzhou, China, discusses sequencing IO and radiotherapy in nasopharyngeal carcinoma: ➡️ buff.ly/K24ba3d ⬅️ #ASCO25 #ImmunOnc #hncSM

🎥Cecile Riviere-Cazaux, PhD, highlights the emerging role cfDNA as novel biomarkers in neuro-oncology, noting their ability to detect molecularly defined biomarkers and monitor treatment response: ➡️ buff.ly/xCKCsRY #BTSM #Oncology

🎥Prof. Jun Ma of Sun Yat-sen University Cancer Center, Guangzhou, China, discusses current immunotherapy approaches in nasopharyngeal carcinoma: ➡️ buff.ly/egOS3ia #ASCO25 #ImmunOnc #hncSM

🎥Christina Fotopoulou, MD, PhD, of @imperialcollegeldn.bsky.social highlights accessibility as a key barrier to optimal surgical care in advanced #OvarianCancer: Watch here➡️ buff.ly/yLzNHzG #ESMOGynae25 #GynOnc #GyncSM #CTSM #TrialUpdate #SurgOnc

🎥Aslı Doğa Munzur, BSc, discusses clonal hematopoiesis (CH) as a potential biomarker in #mCRPC ⭐Ongoing work aims to define CH’s role in predicting blood disorder risk & guiding patient selection: ➡️https://buff.ly/Y9FKoJW @ascocancer.bsky.social #ASCO25 #UroOnc #UroSoMe #PCSM

🎥Fabrice André, MD, PhD, argues against continuing the same CDK4/6 inhibitor after progression in HR+/HER2– #BreastCancer Watch here➡️https://buff.ly/6Uqux4A @myesmo.bsky.social #ESMOBreast25 #BCSM

⭐Christina Fotopoulou, MD, PhD, reports TRUST: primary debulking surgery improved PFS in advanced ovarian cancer, though OS was similar across arms: 🎥 buff.ly/DEDNtYW #ESMOGynae25 #GynOnc #GyncSM #CTSM #TrialUpdate #SurgOnc

⭐ Jason Mouabbi, MD, of @mdanderson.bsky.social, shares an overview of key studies in breast cancer presented at #ASCO25: 🎥 buff.ly/0IeuM2Z @ascocancer.bsky.social #BCSM #BreastCancer #CTSM #TrialUpdate #ImmunoOnc

⭐ Swati Kulkarni, MD, discusses the PROMISE study, assessing presurgical use of conjugated CE/BZA in postmenopausal women with ER-positive DCIS: 🎥 buff.ly/FJvSAAR @ascocancer.bsky.social #ASCO25 #BreastCancer #CTSM #TrialUpadte #SurgOnc

⭐ Fabrice André, MD, PhD, shares KEYNOTE-756 results: ➡️ Adding pembrolizumab to neoadjuvant chemo improved pCR in high-risk ER+/HER2- breast cancer. EFS data pending... 🎥 buff.ly/0R25Yjb #ESMOBreast25 #BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc

⭐ Felix Hilpert, MD, stresses that age/frailty shouldn’t preclude ovarian cancer therapy: chemo & surgery can extend survival in older pts: 🎥 buff.ly/MUxPkAI #ESMOGynae25 #GynOnc #GyncSM

⭐ Yue Che, MD, shares RAISN trial: ICG-guided sentinel node biopsy is feasible & well tolerated in stage I testicular cancer, aiming to reduce chemo use: 🎥 buff.ly/kF09jHH #EAU25 #UroOnc #UroSoMe #CTSM #TrialUpdate #TSCsm

⭐ Michael Gnant, MD, FACS, reviews long-term endocrine therapy in HR+ breast cancer: benefit for high-risk pts, ovarian suppression in ASTRRA, & elinzanetant for vasomotor symptoms: 🎥 buff.ly/hfp5orD @ascocancer.bsky.social #ASCO25 #BreastCancer #BCSM #CTSM #TrialUpdate

🎥 Domenica Lorusso, MD, PhD, reports relacorilant + nab-paclitaxel improved PFS & OS in platinum-resistant ovarian cancer w/ consistent safety: ➡️https://buff.ly/M7ojYej #ESMOGynae25 #GynOnc #GyncSM #CTSM #TrialUpdate

🎥 Peter Albers, MD, comments on PROBASE: men with negative biopsy unlikely to develop prostate cancer within 5 yrs. Doubling PSA values key to refining high-risk group & avoiding overdiagnosis. ➡️ buff.ly/4gKsdFN #EAU25 #UroOnc #UroSoMe #PCSM #CTSM #TrialUpdate

🎥 Alberto Farolfi, MD, reports ctDNA did not align with tissue molecular analysis in the RAMP 201 trial for cervical cancer. Highlights limitations of ctDNA as a reliable biomarker in this setting: ➡️ buff.ly/pQUGuhR #ESMOGynae25 #GynOnc #Gyncsm

🎥 Stephen Bagley, MD, MSCE, of @upenn.edu, highlights the potential of CSF collection in brain cancer trials to advance biomarker development. ⭐ Systematic studies collecting tumor tissue, blood & CSF could clarify its role in guiding care Learn more here ➡️ buff.ly/2aTp3iP #Oncology #BTSM

🎥 Samer Srour, MB ChB, MS, of @mdanderson.bsky.social, discusses IVS-3001, an autologous CAR T targeting HLA-G in advanced solid tumors. Phase I/IIa trial evaluates safety, PK, and early efficacy: Watch➡️https://buff.ly/KsUmJh8 @ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc #CTSM #TrialUpdate

🎥Nadia Hindi, MD, highlights challenges in comparing ICIs vs antiangiogenic therapy in ultra-rare sarcomas. Limited data & lack of pure monotherapy cohorts make conclusions difficult—randomized trials are needed: ➡️https://buff.ly/utlNO0r⬅️ @ascocancer.bsky.social #ASCO25 #ImmunoOnc #scmSM

🎥Cecile Riviere-Cazaux, PhD, highlights the role of CSF-based biomarkers in brain tumor trials. Pairing liquid biopsies with tissue biomarkers may optimize use & benchmarking. ➡️https://buff.ly/I2URhgn⬅️ #BTSM #Oncology

🎥Can biomarkers guide T-DXd use in metastatic breast cancer? ⭐ Paolo Tarantino, MD, of @danafarber.bsky.social reports: 🔹More HER2 mRNA/protein → longer benefit 🔹High Topo1 → worse outcomes in HER2⁻ disease ➡️https://buff.ly/G4wnu14 @ascocancer.bsky.social #ASCO25 #BreastCancer #BCSM #ImmunoOnc

🎥 Dr Suneel Kamath from @clevelandclinic.bsky.social addresses cancer research funding disparities: current allocation driven by advocacy. ➡️Proposes burden-based, criteria-driven approach to ensure equity across diseases Watch🔗https://buff.ly/d2uKbEB @ascocancer.bsky.social #ASCO25 #Oncology

🎥Dr Inimfon Jackson from @mdanderson.bsky.social discusses disparities in chemo acceptance: ➡️Greatest in uninsured/publicly insured & Black patients. Advocates trust-building, early risk ID & informed decision support. 🔗 buff.ly/nttGH5r @ascocancer.bsky.social #ASCO25 #Oncology

🎥 @janichinmay.bsky.social explores alcohol’s role in cancer mortality: ➡️Calls for age/geography–stratified analyses & focus on mechanisms incl. microbiome & ICI interaction. Learn more here🔗 buff.ly/zcvqHJd @ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc

🎥 Xiaoqian Nie, PhD, reports Phase I data: ➡️Erythrocyte–antibody conjugates show stronger antitumor activity & better safety vs PD-1 antibodies in checkpoint-refractory cancers. Promising novel IO strategy 🔗 buff.ly/cD7UDXr @ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc #CTSM #TrialUpdate

🎥 Dr John Paul Shen (@mdanderson.bsky.social) compares methylation-based tissue-free ctDNA assays vs tissue-reliant approaches. ➡️ Sensitivity varies by tumor site & mutation profile—trials needed to define accuracy in MRD detection. 🔗 buff.ly/cGkX0l2 @ascocancer.bsky.social #ASCO25 #Oncology

🎥 Prof. Francois Doz (@institutcurie.bsky.social) emphasizes precision medicine in pediatric cancer ➡️Trials like iMATRIX Alectinib show promise, but rapid molecular profiling at diagnosis remains a barrier to real-world adoption. 🔗 buff.ly/qJueBU3 @ascocancer.bsky.social #ASCO25 #Oncology #CTSM

🎥 Manmeet Ahluwalia, MD, notes the shift in brain metastasis care: from surgery & WBRT ➡️ targeted therapies & ICIs. Next: combinations with ADCs + ICIs while balancing radiation toxicity. 🔗 buff.ly/Q988SOT @ascocancer.bsky.social #ASCO25 #ImmunoOnc #Oncology #SurgOnc

🎥 Mario Perro, PhD, highlights GRC 65327, a selective Cbl-b inhibitor: 🚀 Boosts T/NK cell activity, restores T cell function & enhances anti–PD-1 responses in solid tumor models. Favorable safety profile supports further study 🔗 buff.ly/hBycSv4 @theaacr.bsky.social #AACR25 #Oncology #ImmunoOnc

🎥 Manas Pustake, MD, highlights disparities in cancer screening access for LGBTQ+ populations vs. non-LGBTQ+ groups in the US, emphasizing the need for targeted interventions: ➡️ buff.ly/5ti0xQr ⬅️ @ascocancer.bsky.social #ASCO25 #Oncology

🎥 Valentina Marulanda Corzo, MD, discusses findings from early-phase trials assessing baseline and follow-up PSMA PET parameters in patients with mCRPC treated with 225Ac-J591: ➡️ buff.ly/777PV9f ⬅️ @ascocancer.bsky.social #ASCO25 #PCSM #UroOnc #UrsoSoMe #TrialUpdate #CTSM

🎥Michael Ong, MD, BSc, FRCPC, highlights the prognostic role of PSA in PC: levels >0.2 may signal worse outcomes, but treatment decisions shouldn’t be based on PSA alone. More research needed, especially for low-PSA patients buff.ly/zZSr2sp @ascocancer.bsky.social #ASCO25 #PCSM #UroOnc #UroSoMe

🎥 Angeles Secord, MD, of @dukecancer.bsky.social shares final Phase II PICCOLO results: mirvetuximab soravtansine shows durable responses & good survival in FRα+ platinum-sensitive ovarian cancer: ➡️https://buff.ly/ysRSWzX⬅️ @ascocancer.bsky.social #ASCO25 #GynOnc #GynSM #TrialUpdate #CTSM

🎥Reena Thomas, MD, PhD, on the future of glioblastoma treatment: ⭐Vaccine-based & stem cell–delivered immune therapies ⭐Combining immune & targeted approaches ⭐Using AI to identify early responders & personalize care ➡️ buff.ly/Kq8dzEE ⬅️ @ascocancer.bsky.social #ASCO25 #BTSM #ImmunoOnc